Current Affairs Topics Archive
International Relations Economics Polity & Governance Environment & Ecology Science & Technology Internal Security Geography Social Issues Art & Culture Modern History

NPPA allows 0.64% MRP hike on essential medicines based on WPI

March 26, 2026 6 min read Economics Polity & Governance GS2 (Governance Health Policy) and GS3 (Indian Economy)
On This Page ▼

What Happened

  • The National Pharmaceutical Pricing Authority (NPPA) announced that manufacturers of scheduled (essential) medicines may increase their Maximum Retail Price (MRP) by 0.64% with effect from April 1, 2026.
  • This revision is mandated under Paragraph 16(2) of the Drugs (Prices Control) Order, 2013 (DPCO 2013), which allows annual MRP revision of scheduled formulations based on the movement of the Wholesale Price Index (WPI) — no prior government approval is required for this revision.
  • The WPI for all commodities showed an annual change of +0.64956% during calendar year 2025 over 2024, as computed by the Office of the Economic Adviser, DPIIT, Ministry of Commerce.
  • The NLEM (National List of Essential Medicines) contains approximately 900 formulations — including painkillers, antibiotics, anti-infectives, and chronic disease drugs — whose prices are regulated by the NPPA; all are covered by this revision.
  • The hike comes as pharmaceutical companies face cost pressures from supply disruptions linked to the West Asia conflict and rising input material costs.

Static Topic Bridges

NPPA — Mandate, Structure, and Drug Price Control Mechanism

The National Pharmaceutical Pricing Authority (NPPA) is an attached office of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. It was established in 1997 to fix, revise, and enforce prices of pharmaceutical products in India. The NPPA administers the Drugs (Prices Control) Order (DPCO), currently DPCO 2013, issued under the Essential Commodities Act, 1955 (ECA 1955). Section 3 of the ECA 1955 empowers the Central Government to regulate the production, supply, distribution, and pricing of "essential commodities" — pharmaceuticals are classified as essential commodities.

  • NPPA established: 1997 under the Ministry of Chemicals and Fertilizers
  • Parent legislation: Essential Commodities Act, 1955 — Section 3 (powers to control essential commodity prices)
  • Instrument: Drugs (Prices Control) Order, 2013 (DPCO 2013) — issued under Section 3 of ECA
  • DPCO 2013 replaced DPCO 1995
  • NPPA functions: Fix ceiling prices for scheduled formulations; monitor unscheduled drug prices; prosecute violations
  • Administering ministry: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers

Connection to this news: The 0.64% MRP hike is entirely within NPPA's DPCO 2013 framework — Paragraph 16(2) makes this an automatic, ministerially-notified revision tied to WPI data, not a discretionary pricing decision.

NLEM and Scheduled Formulations — What They Are and How Prices Are Controlled

The National List of Essential Medicines (NLEM) is periodically revised by the Ministry of Health and Family Welfare based on recommendations from expert committees. Medicines listed in the NLEM become "scheduled formulations" under DPCO 2013 — their prices are subject to ceiling price regulation by the NPPA. The ceiling price is calculated using a market-based formula: the simple average of all branded medicines in that formulation with more than 1% market share, adjusted for trade margin. Non-scheduled medicines (not in NLEM) can have prices monitored but not regulated; manufacturers can set their own MRP subject to annual 10% cap increase.

  • NLEM 2022: 384 medicines across 27 therapeutic categories (the most recent revision)
  • DPCO 2013, Para 4-9: Formula for fixing ceiling prices of scheduled formulations
  • ~900 formulations affected: NLEM medicines + combination formulations (multi-ingredient products listed in Schedule I)
  • Non-scheduled formulations: Subject only to price monitoring; can increase MRP by up to 10% annually (DPCO Para 20)
  • Ceiling price = sum of (price × market share of qualifying brands) / total market share, plus 16% trade margin
  • Manufactured under Schedule I of DPCO 2013: Includes single-ingredient NLEM drugs + approved combinations

Connection to this news: The 0.64% WPI-linked revision applies to all ~900 scheduled formulations in Schedule I of DPCO 2013 — this is a narrow, formula-driven hike compared to the broader discretionary pricing freedom available for non-scheduled medicines.

WPI as a Price Index — Mechanism and Role in Policy

The Wholesale Price Index (WPI) measures price changes at the wholesale (producer) level — it tracks the average change in prices of goods at the first point of commercial transaction. The WPI in India has a base year of 2011-12 and is compiled by the Office of the Economic Adviser (OEA), DPIIT (Department for Promotion of Industry and Internal Trade). It covers three broad categories: Primary Articles (22.6% weight), Fuel and Power (13.2%), and Manufactured Products (64.2%). The WPI is distinct from the Consumer Price Index (CPI), which measures retail-level prices — the CPI is used for monetary policy (inflation targeting by RBI). The DPCO links drug price revision to WPI (not CPI) because pharmaceutical raw materials are manufactured products.

  • WPI base year: 2011-12 (revised base)
  • WPI computed by: Office of Economic Adviser, DPIIT, Ministry of Commerce and Industry
  • WPI categories: Primary Articles (22.6%), Fuel & Power (13.2%), Manufactured Products (64.2%)
  • WPI used for: Drug price revisions (DPCO), some contract escalation clauses, dearness allowance calculations
  • CPI (Consumer Price Index): Retail-level prices; used by RBI for inflation targeting (target: 4% ± 2%)
  • WPI 2025 vs. 2024: +0.64956% (annual change, all commodities)
  • Divergence: CPI and WPI often diverge — WPI reflects input/producer prices; CPI reflects consumer-level prices

Connection to this news: The 0.64% hike reflects the WPI's near-flat trajectory in 2025 — a year of low wholesale-level inflation — meaning essential medicine prices rise by less than 1%, providing relative price stability for patients on regulated drugs.

Pharmaceutical Regulation and Access to Medicines — Policy Linkages

India's drug pricing policy balances two competing objectives: ensuring affordable access to medicines (especially for low-income populations) and maintaining viability of the pharmaceutical manufacturing sector. The Pharmaceutical Policy 2002 and the NLEM framework represent the access side; industry representations for cost-recovery represent the viability side. India is the world's third largest pharmaceutical producer by volume and supplies ~20% of global generic medicines — drug pricing policy has both domestic health and global supply chain implications. Price controls through DPCO apply only to formulations listed in NLEM; the vast majority of the pharmaceutical market (by value) is unregulated.

  • India's pharma rank: 3rd largest by volume; 14th by value (2024 estimates)
  • Generic medicines: India supplies ~60% of global vaccine demand and ~20% of generic exports
  • NLEM coverage: ~900 formulations cover roughly 20-25% of the total pharmaceutical market by volume
  • Price monitoring for non-NLEM drugs: NPPA's Market Based Pricing (MBP) Cell tracks unusual price increases
  • Trade margin rationalisation (TMR): Government initiative to cap wholesale and retail trade margins for non-scheduled drugs — reduces consumer burden without formal price control
  • Universal Health Coverage (SDG 3.8): Access to essential medicines at affordable prices — NLEM/DPCO is India's primary tool for SDG 3.8 compliance

Connection to this news: The annual WPI-linked revision is the principal mechanism ensuring that ceiling prices for essential medicines do not become unviable for manufacturers over time — without this annual escalation, manufacturers would either exit or seek administrative price revisions individually, undermining the system's efficiency.

Key Facts & Data

  • NPPA MRP revision: +0.64% effective April 1, 2026
  • Legal basis: Paragraph 16(2), Drugs (Prices Control) Order, 2013 (DPCO 2013)
  • Parent legislation: Essential Commodities Act, 1955 — Section 3
  • WPI change (2025 over 2024): +0.64956% (annual; all commodities; source: OEA, DPIIT)
  • Formulations covered: ~900 scheduled formulations (Schedule I, DPCO 2013)
  • NLEM (current): NLEM 2022 — 384 medicines, 27 therapeutic categories
  • NPPA established: 1997; attached office under Department of Pharmaceuticals
  • Prior approval needed: No — Paragraph 16(2) allows manufacturers to revise MRP automatically based on WPI
  • Effective date: April 1, 2026 (aligned with financial year start — standard for DPCO revisions)
  • Drug categories included: Painkillers, antibiotics, anti-infectives, chronic disease drugs (cardiovascular, diabetes, etc.)
  • WPI base year: 2011-12
  • DPCO 2013 replaced: DPCO 1995